SCHEMBL2534045

SCHEMBL2534045

CCOc1ccc2[nH]cc(CCN3C(=O)c4ccccc4C3=O)c2c1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.69
▸ MEN1 O00255 5/20 0.69
▸ KMT2A Q03164 5/20 0.69
▸ LMNA P02545 4/20 0.69
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ GAA P10253 2/20 0.66
▸ NPC1 O15118 3/20 0.64
▸ RAB9A P51151 3/20 0.64
▸ ALDH1A1 P00352 4/20 0.63
▸ HTT P42858 1/20 0.60
▸ TDP1 Q9NUW8 2/20 0.57
▸ TP53 P04637 1/20 0.57
▸ HPGD P15428 2/20 0.49
▸ HTR1A P08908 2/20 0.48
▸ HTR1B P28222 2/20 0.48
▸ HTR1D P28221 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.47
▸ TRPM8 Q7Z2W7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148291 0.91 MAPT (0.70) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL8229566 0.88 MAPT (0.87) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL2536283 0.87 GAA (0.67) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL31660992 0.87 GAA (0.67) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL2539868 0.86 MAPT (0.62) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL5148298 0.85 MAPT (0.68) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL10521905 0.84 POLB (0.55) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL26826151 0.83 MAPT (0.65) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL8880777 0.82 HTR1A (0.66) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL8880990 0.81 MAPT (0.69) MAPTMEN1KMT2ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 — — EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 — — US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 — — US disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 — — EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 — — EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 — — US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B MAPT 3701/4885MEN1 1889/4885KMT2A 1269/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B MAPT 3701/4885MEN1 1889/4885KMT2A 1269/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B MAPT 3701/4885MEN1 1889/4885KMT2A 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback